ALPHAGAN Drug Patent Profile

Which patents cover Alphagan, and what generic alternatives are available?

Alphagan is a drug marketed by Allergan and Abbvie and is included in four NDAs.

The generic ingredient in ALPHAGAN is brimonidine tartrate. There are eleven drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the brimonidine tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alphagan

A generic version of ALPHAGAN was approved as brimonidine tartrate by BAUSCH AND LOMB on May 28^th, 2003.

Summary for ALPHAGAN

US Patents:	0
Applicants:	2
NDAs:	4

US Patents and Regulatory Information for ALPHAGAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	ALPHAGAN	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	020613-001	Sep 6, 1996		DISCN	Yes	No
Abbvie	ALPHAGAN P	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	021262-001	Mar 16, 2001	AT	RX	Yes	Yes
Allergan	ALPHAGAN	brimonidine tartrate	SOLUTION/DROPS;OPHTHALMIC	020490-001	Mar 13, 1997		DISCN	No	No

International Patents for ALPHAGAN

See the table below for patents covering ALPHAGAN around the world.

Country	Patent Number	Title	Estimated Expiration
China	1335773
Germany	69636012
European Patent Office	1611891	Utilisation de (2-imidazolin-2-ylamino) quinoxalines pour le traitement de pathologie oculaire nerveuse (Use of (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury)

Supplementary Protection Certificates for ALPHAGAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	300683	Netherlands		PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225

Investment Scenario and Fundamentals Analysis for Alphagan (Brimonidine Ophthalmic Solution)

Last updated: February 23, 2026

What Is the Market Position of Alphagan?

Alphagan (brimonidine tartrate ophthalmic solution) is a prescription medication indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is marketed primarily by Allergan, now part of AbbVie, and competes in a mature market with established alternatives like prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors.

Market estimates project the global glaucoma drug market will reach USD 6.8 billion by 2027, growing at a compound annual growth rate (CAGR) of approximately 4.5% from 2020 to 2027.[1] Alphagan holds a significant share but faces increased competition due to new drug launches and patent expirations.

How Does Alphagan Stand in Revenue and Patents?

Alphagan generated USD 175 million globally in 2022, representing a stable revenue stream over recent years, with slight declines attributed to generic options.[2] The drug’s patent protections expired in the U.S. in 2018, leading to increased generic competition, which impacted sales. However, AbbVie’s ongoing efforts in line extensions and combination therapies support revenue stability.

Patent and Regulatory Timeline

Year	Event
1996	FDA approval of Alphagan I
2018	Patent expiration in the U.S.
2022	Launch of combination drug Alphagan-P (brimonidine + timolol)
2025	Patent expiry in other key markets

The combination therapy Alphagan-P, launched in 2022, aims to maintain market share by offering convenience and improved efficacy, potentially delaying decline due to generic competition.

What Are the R&D and Pipeline Dynamics?

AbbVie’s pipeline includes next-generation alpha-2 adrenergic receptor agonists and novel delivery systems, such as sustained-release devices. Recent investments include:

• A phase III trial for a sustained-release brimonidine implant (scheduled completion 2024)
• Combination therapies that improve patient adherence
• Novel formulations designed to reduce systemic absorption and side effects

These innovations could extend product lifecycle and competitive advantages, particularly if approved and adopted clinically.

What Is the Competitive Environment?

Major competitors include:

• Lumigan (bimatoprost)
• Xalatan (latanoprost)
• Travatan (travoprost)
• Cosopt (dorzolamide/timolol)

While Alphagan holds about 18% of the global glaucoma medication market,[3] sales are challenged by generics and newer drugs exhibiting improved patient compliance.

What Are the Regulatory and Pricing Trends?

Pricing trends in developed markets show a decline for proprietary glaucoma drugs due to discount pressures and increased use of generics. For branded therapies like Alphagan, promotional efforts and formulary positioning influence revenue.

Regulatory actions involve price reductions and reimbursement negotiations, especially in markets like the US (Medicare), Europe, and Japan. The strategic shift toward combination therapies is partly driven by reimbursement incentives to prevent non-compliance.

What Are Key Investment Risks?

• Patent expirations in core markets (U.S., Europe)
• Competition from generics and biosimilars
• Slower-than-expected adoption of formulations in development
• Potential regulatory hurdles in new delivery systems

What Are the Opportunities?

• Launch of next-generation sustained-release formulations
• Expansion into emerging markets with increasing ophthalmology access
• Strengthening of combination therapy portfolio to offset generic erosion

What Is the Financial Outlook?

AbbVie maintains a diversified ophthalmology portfolio, with eye care contributing roughly 12% of total revenue in 2022.[4] Stabilized revenues for Alphagan, combined with pipeline advancements, suggest potential mid-term growth if new formulations succeed commercially. R&D expenses for ophthalmology typically approximate 15% of total R&D spend, aligning with industry norms.

Key Takeaways

• Alphagan remains relevant but faces patent expiry and generic competition.
• Pipeline innovation, particularly sustained-release formulations, may extend product lifecycle.
• Market growth is steady but challenged by pricing pressures and market share erosion.
• Combination therapies represent strategic leverage against competitors.
• Investment stability depends on regulatory success and adoption of new delivery systems.

FAQs

1. When will Alphagan's patents expire in major markets?
2. How do generics affect Alphagan’s revenue?
3. What are the prospects for Alphagan’s pipeline products?
4. How does the competition impact Alphagan’s market share?
5. What regulatory hurdles could influence Alphagan's future sales?

---

References

[1] Grand View Research. (2021). Glaucoma Drugs Market Size, Share & Trends.
[2] AbbVie. (2023). Annual Financial Report.
[3] IQVIA. (2022). Ophthalmology Market Data.
[4] AbbVie. (2022). Quarterly Earnings Reports.

Note: Data cited from publicly available industry reports and company disclosures as of 2023.